Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
LONDON and PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the appointments of David Bryant and Richard Hughes as Non-Executive Directors with immediate effect.
David Bryant is a highly experienced international pharmaceutical executive with over 35 years in the industry. He has a strong track record in commercial leadership roles at GSK and Pfizer and was one of the original management team at Clinigen Group, from its 2012 IPO on AIM to its sale for $1.6bn in 2022. David is currently an Advisor to Healthcare Royalty (HCRx), a US-based healthcare focused private investment business.
Richard Hughes has had a long and successful career in UK capital markets with over 30 years' corporate finance experience, including IPOs, equity capital raising and M&A for both public and private companies. He was previously a founder shareholder and a director of boohoo.com and a majority shareholder of Crawford Healthcare, a UK-based advanced wound care and dermatology company, which was acquired by Acelity in June 2018. He is a shareholder and director of numerous private companies operating across a range of sectors. Richard founded Zeus Capital, an independent financial services group, in 2003 and is a director of Zeus Group.
Shaun Chilton, Non-Executive Chairman, commented:
'As Avacta completes its transformation into a dedicated pure play therapeutics company, focused on advancing our unique pre|CISION® platform for the benefit of patients, it needs seasoned and expert guidance. David and Richard have many years' experience and proven track records in pharmaceutical development and commercialization and capital markets respectively. Their collective expertise will significantly enhance the Board's capabilities as we focus on the strategic opportunities within our innovative pipeline to build long-term shareholder value.'
commented:
'I am looking forward to working closely with the executive management team on Avacta's exciting technology and leveraging my commercial expertise. With the recent advances from the pre|CISION platform just published and the second program entering the clinic soon, the timing is ideal for me to join the Board.'
added:
'I am delighted to be appointed as a Director. The business has a proprietary delivery platform in pre|CISION® that I believe will have a significant impact on the standard of care across a range of therapeutics, whilst limiting the harmful side effects that so many patients experience. I look forward to utilizing my experience in both fundraising and the scaling of businesses to assist the executive management team in delivering value for all shareholders.'
For further information from Avacta Group plc, please contact:
Avacta Group plcMichael Vinegrad, Group CommunicationsDirector
www.avacta.com
Peel Hunt (Nomad and Joint Broker)James Steel / Chris Golden
www.peelhunt.com
Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers
www.panmureliberum.com
ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert
avacta@icrhealthcare.com
Investor ContactRenee Leck THRUST Strategic Communications
renee@thrustsc.com
Media ContactCarly ScadutoCarly Scaduto Consulting
Carly@carlyscadutoconsulting.com
About Avacta - www.avacta.comAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
Appendix 1: Further disclosures regarding David Bryant
Avacta also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies.
Full name: David John Bryant
Age: 58 years
Current directorships/partnerships:
60 Niton Street (Freehold) Limited
60 Niton Street RTM Ltd
Mulberry Capital Management Ltd
Previous directorships/partnerships held in the past 5 years:
Clinigen Limited
Nupharm Group Limited
Pern Consumer Products Limited
Protomed Limited
Quantum Pharma 2014 Limited
Quantum Pharmaceutical Limited
Quantum Pharma Group Limited
Quantum Pharma Holdings Limited
Quantum Specials Trustee Limited
Triley Bidco Limited
Triley Midco Limited
Triley Midco 2 Limited
U L Medicines Limited
Protomed Limited entered into a creditors' voluntary winding up process in February 2019. There were no secured or preferential creditors and as at April 2025 claims of c. £4.1m from unsecured creditors had been received which were in the process of being agreed and distributed.
David Bryant does not hold any ordinary shares in Avacta.
There are no other disclosures required in connection with the appointment David John Bryant under Schedule Two(g) of the Aim Rules for Companies.
Appendix 2: Further disclosures regarding Richard Hughes
Avacta also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies.
Full name: Richard Ian Hughes
Age: 57 years
Current directorships/partnerships:
Andratx Property Limited
Bidco 2 Limited
Bidco 3 Limited
Bidco 4 Limited
Dakarts Limited
Elpis Holdings Limited
Eternal Time Limited
Irwell Investments Limited
Medusa 19 Limited
Medusa 19 Group Limited
Medusa 19 Healthcare Limited
Medusa Asset Management Limited
Medusa Management Services Limited
Medusa Partners LLP
Oakdate Limited
Palatine Private Equity LLP
RHDL Limited
Saturn Asset Management Limited
Saturn Group Holdings Limited
Saturn Pass Limited
Saturn Passport Limited
Stratford Place Property Investments Ltd
Zeus Group Limited
Previous directorships/partnerships held in the past 5 years:
Newco (Huntingdon Street Nottingham) Limited
The following disclosures are made in accordance with paragraphs (g) (v) and (vi) of Schedule Two of the AIM Rules:
Richard Hughes was:
appointed a director of Catalyst Securities Limited on 3 February 2006, a company incorporated in England. The company was placed into administration on 21 April 2011 and was subsequently dissolved on 14 November 2018, with approximately £9.3 million owing to creditors;
appointed a director of Catalyst Securities No.2 Fund Limited on 3 February 2006, a company incorporated in England. The company was placed into administration on 13 September 2010 and was subsequently dissolved on 15 June 2013, with approximately £1.5 million owing to creditors;
appointed a director of Catalyst Investments Limited on 18 January 2006, a company incorporated in England. The company entered a creditors' voluntary liquidation on 17 June 2011 and was subsequently dissolved on 23 April 2014, with approximately £9.5 million owing to creditors;
appointed a director of Procurasell Holdings Limited on 30 October 2007, a company incorporated in England. The company entered a compulsory liquidation on 17 June 2009 and was subsequently dissolved on 24 August 2010;
appointed a director of The Debt Advisor Group plc on 9 April 2003, a company incorporated in England. The company was placed into administration on 29 June 2007 and was subsequently dissolved on 10 April 2011, with approximately £2.3 million owing to unsecured creditors;
appointed an LLP designated member of My SPA Liverpool LLP, a limited liability partnership incorporated in England, on 5 November 2008. The partnership entered a creditors' voluntary liquidation on 20 October 2009 and was subsequently dissolved on 25 May 2011, with an estimated £64,633 owing to unsecured creditors; and
appointed an LLP designated member of My SPA Chesire LLP, a limited liability partnership incorporated in England, on 1 December 2008. The partnership entered a creditors' voluntary liquidation on 22 April 2010 and was subsequently dissolved on 16 July 2012, with approximately £31,000 owing to unsecured creditors.
Richard Hughes does not hold any ordinary shares in Avacta.
There are no other disclosures required in connection with the appointment Richard Ian Hughes under Schedule Two(g) of the Aim Rules for Companies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
6 toilet habit changes you should always see a doctor about
No one enjoys talking about bowel movements. But ignoring the signs your body is trying to send you can mean putting off a diagnosis you really need to hear. Just ask TOWIE star Chloe Meadows. The reality TV regular recently shared on Dr Oscar Duke's Bedside Manners podcast that she'd spent a decade silently struggling with bleeding, stomach pain and extreme fatigue before finally getting a diagnosis: ulcerative colitis, a chronic condition that causes inflammation and ulcers in the colon. She lived with on-and-off symptoms for years, assuming they'd passed. It wasn't until age 26, when she became visibly unwell, that a blood test led her to A&E and finally, a diagnosis. Meadows' experience is an important reminder that when your toilet habits change – and stay changed – it's time to talk to your GP. Below, we break down six toilet-related red flags that experts say you should never ignore. And no, it's not just about your bowel movements; your wee, urgency levels, and even smells all matter, too. Whether you're suddenly constipated, dealing with constant diarrhoea, or noticing your stool looks different (narrower, paler or greasy), changes that last longer than a few weeks are worth investigating. The NHS advises that ongoing shifts in bowel habits could be linked to anything from diet and stress to Irritable Bowel Syndrome (IBS), coeliac disease or inflammatory bowel disease (IBD). In some cases, persistent symptoms could be a sign of bowel cancer, so don't brush them off. When to see your GP: If your usual routine has changed for more than two to three weeks, especially if it's paired with stomach pain, fatigue, or weight loss. It might be bright red or dark and tarry; either way, it's not something to ignore. Bright red blood can come from piles or small tears, but darker blood might mean there's bleeding higher up in the digestive system. When to see your GP: If you see blood in your poo. You may be offered a stool test, or in some cases, a referral for further checks. If anything feels amiss and suddenly starts to sting, burn or feel uncomfortable, you might assume it's a urinary tract infection (UTI). And often, that's true. But it can also be a sign of kidney stones or bladder issues. Blood in your urine should also be taken seriously, even if it only happens once. When to see your GP: If you have pain while urinating, see blood or feel the urge to go far more often than usual. Needing the loo more often than usual (especially at night), feeling like you can't wait, or leaking a little when you cough, sneeze or laugh could signal an overactive bladder, prostate issues (in men), or pelvic floor dysfunction. These symptoms might feel embarrassing, but they're generally common and manageable with the right support. When to see your GP: If bladder leaks or urgency interfere with your daily life, or if you notice a sudden change in how often you need to go. A little mucus in your stool isn't always a worry, but frequent slimy stools can be a sign of infection or inflammation in your gut. When to see your GP: If mucus appears regularly, especially if it comes with bloating, pain or a change in bowel movements. If going to the toilet has become uncomfortable, painful, or feels like hard work, that's your body waving a red flag. Regular straining can cause or worsen hemorrhoids, but it might also signal bowel issues or even neurological problems affecting your pelvic floor. When to see your GP: If you're straining often, feel like you're not fully emptying your bowels, or notice pain during or after a bowel movement. If you're unsure, remember that everyone has their own baseline of what's 'normal'. However, there are a few simple signs to watch for as a guide. According to the Bladder and Bowel Health Service, healthy bowel movements should be soft, smooth and easy to pass; ideally at least three times a week. You should also be able to urinate without pain or discomfort. If you also notice you're often bloated, tired, straining, or notice blood or mucus, it's time to speak to your GP. Changes might be harmless, but they're always worth checking. Read more on bowel habits: This Poop Chart Will Tell You If Your Bathroom Habits Are Actually Healthy Or If You Need To See A Doctor ASAP (Buzzfeed, 4-min read) How 'blowing bubbles' and 'mooing' can help ease constipation, according to NHS doctor (Yahoo Life UK, 4-min read) Bowel cancer cases in young people rising sharply in England, study finds (PA Media, 4-min read)
Yahoo
13 minutes ago
- Yahoo
Premier League 'under strain' despite record £6.3 bn revenues
The combined revenue of Premier League clubs rose to a record £6.3 billion ($8.5 billion, 7.5 billion euros) in the 2023/24 season, but fan unrest and worsening competitive balance are cause for concern, according to financial experts Deloitte. The rise in income for England's 20 top-flight clubs was fuelled by commercial income surpassing £2 billion for the first time and a rise in matchday revenue beyond £900 million. English clubs continue to enjoy a huge financial advantage over their European rivals. Spain's La Liga, the second highest revenue-generating league, earned just over half that amount at 3.8 billion euros, almost 50 percent of which came from Real Madrid and Barcelona. However, fan protests have become a common sight at Premier League stadiums over rising ticket prices and the squeezing out of local supporters to make way for more tourists willing to spend more for a special matchday experience. "There can be no doubt that the system in English football is under strain," said Tim Bridge, the lead partner in the Deloitte Sports Business Group. "Repeated reports of fan unrest at ticket price and accessibility demonstrate the challenge in the modern era of balancing commercial growth with the historic essence of a football club's role and position in society: as a community asset." There is also uncertainty over the implications of an incoming independent regulator for England's top five leagues. And for the past two seasons, all three promoted clubs from the Championship have been immediately relegated back to the second tier. "The financial implications of the 'yo-yo effect' on clubs, their spending, and overall competitiveness are major factors to address in order to continue attracting high levels of investment across the system," added Bridge in Deloitte's Annual Review of Football Finance. Total revenue of European clubs rose by eight percent in the 2023/24 campaign to 38 billion euros, boosted by increased commercial revenue and stadium developments. The women's game also continues to grow commercially, particularly in England's Women's Super League (WSL). Collective revenues in the WSL rose 34 percent to £65 million in 2023/24 and are projected to reach £100 million in the upcoming season. kca/nf Sign in to access your portfolio
Wall Street Journal
18 minutes ago
- Wall Street Journal
Tesco Sales Rise as Market Share Increases Despite Tough Competition
U.K. grocer Tesco TSCO 2.60%increase; green up pointing triangle maintained its full-year expectations after sales climbed in its fiscal first quarter, when it continued to gain market share despite fierce competition in the sector. The supermarket chain on Thursday posted 16.38 billion pounds ($22.19 billion) in group sales excluding value-added tax and fuel for the 13 weeks ended May 24, rising 4.6% on a like-for-like basis.
